| Identification | Back Directory | [Name]
PD-1-IN-17 | [CAS]
1673560-66-1 | [Synonyms]
AUPM170
PD-1-IN-17
PD1IN17,PD 1 IN 17
2-[[4-Amino-1-[5-(1-amino-2-hydroxypropyl)-1,3,4-oxadiazol-2-yl]-4-oxobutyl]carbamoylamino]-3-hydroxypropanoic acid
L-Serine, N-[[[(1S)-4-amino-1-[5-[(1S,2R)-1-amino-2-hydroxypropyl]-1,3,4-oxadiazol-2-yl]-4-oxobutyl]amino]carbonyl]- | [Molecular Formula]
C13H22N6O7 | [MDL Number]
MFCD31715409 | [MOL File]
1673560-66-1.mol | [Molecular Weight]
374.35 |
| Chemical Properties | Back Directory | [density ]
1.491±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: soluble | [form ]
A solid | [pka]
3.46±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
PD-1-IN-17 is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM[1]. | [storage]
Store at -20°C | [References]
[1] Pottayil Govindan Nair Sasikumar, et al. 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators. WO2015033301A1. |
|
|